Multiple Sclerosis (MS)AROMA-MSNCT07599189

Essential Oils for Urinary Symptoms in Multiple Sclerosis Patients

A study testing Essential Oil Blend (Lavender, Rosemary) and Neutral Carrier Oil (Apricot Kernel Oil) in people with Multiple Sclerosis (MS) and Neurogenic Bladder Disorder, run by University of Oran 1 at 2 sites in Algeria.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts

Official record

Search all trials

Trial summary

The goal of this clinical trial is to learn if essential oil aromatherapy works to improve urinary symptoms in adults with multiple sclerosis. It will also learn about the safety of essential oil use in this population. Read more about this study

Who is it for?: Any age
Conditions the study is for: Multiple Sclerosis (MS), Neurogenic Bladder Disorder, Urinary Incontinence (UI)
What is being tested?: Essential Oil Blend (Lavender, Rosemary) and Neutral Carrier Oil (Apricot Kernel Oil)
Could I receive a placebo?: Yes, some participants may receive a placebo
How many people: 60 participants
Where: 2 sitesAlgeria
Study dates: Sep 2026to Mar 2027
Phase: Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages Any age
All sexes
No healthy volunteers
Child, Adult, Older adult

Who may be able to join

Confirmed diagnosis of Multiple Sclerosis (any form)
Documented lower urinary tract symptoms defined by an Overactive Bladder Symptom Score (OABSS) ≥ 3 at screening
Age between 18 and 65 years
Willing and able to provide written informed consent
Capable of performing daily topical self-application of the study oil, or having a caregiver available to assist throughout the study period

Who cannot join

Active urinary tract infection confirmed by urine culture at screening
Pre-existing urological condition unrelated to Multiple Sclerosis (e.g., bladder cancer, benign prostatic hyperplasia, or interstitial cystitis)
Known allergy or hypersensitivity to essential oils, apricot kernel oil, lavender, or rosemary
Active skin lesions, wounds, or dermatological conditions on the lower abdomen at the intended site of application
Pregnancy, breastfeeding, or planning to become pregnant during the study period
Significant cognitive impairment preventing understanding of study procedures or completion of questionnaires
Current use of an indwelling urinary catheter or practice of intermittent self-catheterization

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Zitouni-Nourine Saida Hanane contact

+213556623080

zitouni.saida@univ-oran1.dz

Algeria2 sites

Aboubakr abdelmadjid
Oran, Oran Province, 31000
Aboubakr Abdelmadjid, Professor, (+213) 041 70 50 92, contact@ehuoran.dz
Zitouni-Nourine Saida Hanane
Oran

Other trials in Algeria

About this study

Official title: Efficacy and Safety of Essential Oil Aromatherapy on Neurogenic Lower Urinary Tract Symptoms in Patients With Multiple Sclerosis: A Randomized Single-Blind Placebo-Controlled Clinical Trial.

The main questions it aims to answer are:

Does essential oil aromatherapy reduce urinary urgency, frequency, and incontinence episodes in participants with multiple sclerosis?
What medical problems do participants have when using essential oil aromatherapy?

Researchers will compare essential oil aromatherapy to a placebo (a look-alike neutral oil with no therapeutic properties) to see if essential oil aromatherapy works to improve urinary symptoms in multiple sclerosis patients.

Participants will:

Use essential oil aromatherapy or a placebo oil every day for 6 weeks
Complete a urinary symptom scales to record the frequency, urgency, and any leakage episodes each day
Fill out quality of life questionnaires at the beginning and end of the study

Conditions: Multiple Sclerosis (MS), Neurogenic Bladder Disorder, Urinary Incontinence (UI), Urinary Urgency, Lower Urinary Tract Symptoms (LUTS)
Being tested: Essential Oil Blend (Lavender, Rosemary), Neutral Carrier Oil (Apricot Kernel Oil)
Medical subject headings: Multiple Sclerosis, Urinary Bladder, Neurogenic, Urinary Incontinence, Lower Urinary Tract Symptoms

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Essential Oil Blend (Lavender, Rosemary)Other
This intervention consists of a standardized topical blend of Lavender (Lavandula angustifolia) at 3% and Rosemary (Rosmarinus officinalis) at 2%, diluted in apricot kernel oil as a carrier. The blend was formulated to target neurogenic lower urinary tract symptoms in patients with multiple sclerosis, based on the antispasmodic properties of Lavender and the neuromodulatory and anti-inflammatory properties of Rosemary. The essential oils used are batch-controlled for chemical purity and concentration. The blend is applied topically via gentle circular massage on the lower abdomen, for a total duration of 6 consecutive weeks. This specific combination, route of administration, and target population distinguish this intervention from other aromatherapy studies that have used single oils, inhalation methods, or non-neurological populations.
Neutral Carrier Oil (Apricot Kernel Oil)Other
This intervention consists of pure Apricot Kernel oil, used as an inert placebo comparator. The placebo oil contains no active essential oils or therapeutic compounds. It is identical to the experimental intervention in terms of appearance, color, viscosity, volume, packaging, and method of application, ensuring effective masking of participants and outcome assessors. The placebo oil is applied topically via gentle circular massage on the lower abdomen, for a total duration of 6 consecutive weeks, mirroring exactly the administration protocol of the experimental arm.

Study groups in NCT07599189
Study group	Role	What they receive
Essential Oil Aromatherapy Group	Experimental	Not described Receives: Other: Essential Oil Blend (Lavender, Rosemary)
Placebo Oil Group	Placebo comparator	Not described Receives: Other: Neutral Carrier Oil (Apricot Kernel Oil)

What is being measured

The primary outcome is the main question the study is designed to answer.

Overactive Bladder Symptom Score (OABSS)
Overactive Bladder Symptom Score (OABSS) (Overactive Bladder Symptom Score) Scale range: minimum 0 - maximum 15. Higher scores indicate a worse outcome (greater severity of overactive bladder symptoms).
[Time Frame: Baseline and Week 6]
Measured: Baseline, and Week 6
Qualiveen questionnaire
Qualiveen - Urinary Disorder-Specific Quality of Life Questionnaire (Qualiveen, Domain 1: "Bother with Limitations") Scale range: minimum 0 - maximum 4 per item (9 items, total domain score = sum of items ÷ 9).
Higher scores indicate a worse outcome (greater bother related to urinary problems).
[Time Frame: Baseline and Week 6]
Measured: Baseline and Week 6

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

Sep 2026Mar 2027

First posted20 May 2026
Study startSep 2026 (estimated)
Primary completionDec 2026 (estimated)
Study completionMar 2027 (estimated)

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Other trials for Multiple Sclerosis (MS)Studies of the same condition, open and under way.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Supportive care
Allocation: Randomised
Intervention model: Parallel groups
Masking: Double blind
Who is masked: Participant, Outcomes assessor
Enrolment: 60 participants (estimated)

IDs, dates and publications

ClinicalTrials.gov ID: NCT07599189
Sponsor's protocol ID: UO1-HE-SEP-URO-2025-001
Acronym: AROMA-MS
Status last verified: May 2026
First submitted: 4 May 2026
Last updated: 20 May 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Interested in taking part?

Zitouni-Nourine Saida Hanane

+213556623080

zitouni.saida@univ-oran1.dz

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See sites and contacts

Active, not recruiting
Tai Chi Training for Persons With Multiple Sclerosis.
Multiple Sclerosis (MS) - Relapsing-remitting
RecruitingPhase 3
A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
Multiple Sclerosis (MS) Primary Progressive
Not yet recruitingPhase 1/2
C-CAR168, an Autologous Anti-CD20/BCMA Chimeric Antigen Receptor T-Cell Therapy, in Participants With Progressive Multiple Sclerosis Refractory to Standard Therapy
Multiple Sclerosis, Primary Progressive Multiple Sclerosis
Recruiting
At Home Use of Stimulation Suits for Managing MS Symptoms
Multiple Sclerosis, MS (Multiple Sclerosis)
RecruitingPhase 2
A Phase 2a Study of SUN-627 in Participants With Non-Active Secondary Progressive and Primary Progressive Multiple Sclerosis (SPMS/PPMS)
Primary Progressive Multiple Sclerosis, Primary Progressive MS

All Multiple Sclerosis (MS) trials